AI Verdict
LCTX has stronger fundamentals based on our AI analysis.
LE vs LCTX Fundamental Comparison
| Metric | LE | LCTX |
|---|---|---|
| Revenue | $1.2B | $14.6M |
| Net Income | $5.5M | $-63.5M |
| Net Margin | 0.5% | -436.5% |
| ROE | 2.3% | -142.6% |
| ROA | 0.7% | -56.4% |
| Current Ratio | 1.61x | 5.20x |
| Debt/Equity | 0.88x | 0.00x |
| EPS | $0.18 | $-0.28 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
LE vs LCTX: Frequently Asked Questions
Is LE or LCTX a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), LCTX has stronger fundamentals. LE is rated STRONG SELL (88% confidence) while LCTX is rated SELL (88% confidence). This is not investment advice.
How does LE compare to LCTX fundamentally?
LANDS' END, INC. has ROE of 2.3% vs Lineage Cell Therapeutics, Inc.'s -142.6%. Net margins are 0.5% vs -436.5% respectively.
Which stock pays higher dividends, LE or LCTX?
LE has a dividend yield of N/A or no dividend while LCTX has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in LE or LCTX for long term?
For long-term investing, consider that LE has STRONG SELL rating with 88% confidence, while LCTX has SELL rating with 88% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about LE vs LCTX?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For LE vs LCTX, the AI consensus favors LCTX based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.